Genetic Data Does Not Age: Why Your Report Is Worth Revisiting

Most people read their genetic report once: carefully, pencil in hand, perhaps even taking notes. And then they set it aside. A year later the question “has it gone out of date?” arises almost automatically. Say you took the test two years ago, and recently you read that researchers have found new variants linked to cardiovascular risk. Do you need to test again? Have your results changed? The most common mistake is to confuse two different questions: whether your DNA has changed, and whether what we know about it has changed. The answer to the first is always no. The answer to the second is far more interesting.

To understand why a genetic report stays relevant and, at the same time, why it is worth returning to, three things are enough: what in it is fixed, what becomes more precise over time, and in which situations a second reading adds new value. Let us take each in turn.

How to read your report properly and what the figures on the scale mean — How to read your Apixmed Prism report: what the results mean.

DNA Does Not Change — This Is the Basis of the Report’s Permanence

The human genome is fixed at the moment of fertilisation and remains unchanged throughout life. The variants that shape a predisposition to vitamin D deficiency, the particulars of caffeine metabolism or the risk of coeliac disease are written into your DNA once and for all. They are the same in a skin cell, a blood cell and the saliva sample your test was made from.

Imagine the genome as a passport issued at birth. The pages are not rewritten, the stamps do not disappear. What changes is only how states interpret the document: today one stamp means one thing, tomorrow the rules are updated and the same stamp opens new doors. It is the same with genetic data: your result is fixed, but knowledge of what it means accumulates.

There is one exception worth knowing about: somatic mutations, that is, those that arise in particular cells over the course of life through environmental influence or replication errors. They do not appear in a standard genetic report, because that report analyses germline DNA, which is shared by all the cells of the body. Oncology tests that analyse tumour tissue work differently and are a separate field.

[IMAGE 1]

What Changes Over Time: The Science, Not Your Genome

The genetics of complex traits is moving quickly. New large population studies of the GWAS type (Genome-Wide Association Study) are constantly refining which variants are linked to which conditions and how strongly. Polygenic risk profiles, or PRS (Polygenic Risk Score), which underlie most of the figures in a report, are rebuilt as studies produce new data from larger and more diverse samples.

This means two things. A score calculated today on the basis of 150 variants may, three years from now, rest on 400 variants of the same trait, and the numerical result may shift somewhat. And measures that were not in the report before may appear in it later, once the scientific evidence is mature enough for them to be included.

This is why genetic reports are updated — not because your genome has changed, but because our understanding of what matters in it has. Your raw data stay the same, and they can be recalculated against new models without repeat testing.

For a detailed account of how a polygenic risk profile is built and what your score means compared with the population, see the article Polygenic risk (PRS): how it is calculated and what it means.

A Predisposition Is Not a Verdict

There is another dimension to the report’s stability that is often underestimated. A genetic predisposition describes a biological characteristic, not a future scenario. A high predisposition to vitamin D deficiency does not mean you will have a deficiency, just as a predisposition to elevated cholesterol does not mean cardiovascular disease. It means that your body is statistically more vulnerable to a given condition compared with the population under the same external conditions.

This logic does not change with the years. On the contrary, it becomes more useful: the more you know about your lifestyle, your laboratory results and your medical history, the more precisely you can fit the genetic context into the real picture of your health. A report read again after a doctor has identified a particular condition often says more than it did on the first reading.

An important detail: it is not the report that changes, but your context. The same figures that seemed abstract two years ago can, after a change of diet, the start of training or a new diagnosis, become a concrete reference point for action.

For the difference between a genetic predisposition and a diagnosis, and why a high predisposition is not a verdict, see the article Genetic predisposition ≠ diagnosis: how to understand your risk correctly.

When It Is Worth Returning to Your Report

There is no strict rule for how often to review a genetic report. But there are several situations in which a second reading is particularly useful:

• Your lifestyle or diet has changed. If you have started or ended a particular diet, increased your physical load or given up harmful habits, the genetic context will help you understand which changes matter most for your own biology.

• A new symptom or diagnosis has appeared. If a doctor has identified a condition for which your report has a corresponding measure, comparing your genetic predisposition with clinical data gives a fuller picture and may influence the choice of approach to treatment or prevention.

• Family health has changed. If close relatives have developed particular diseases, the genetic measures linked to those conditions are worth reviewing in the light of the new information.

• The report has been updated. If you have received a notice about updated models or newly added measures, that is a reason to reread the report in full: the new ones may turn out to be relevant right now.

• A year or more has passed since your first reading. Even without a specific reason, returning to the report after a long pause often yields new insight: questions that were not there on the first reading have had time to appear.

What Makes a Report More Valuable Over Time

There is a paradox noticed by those who return to their report after several years: it seems more precise and more useful than it did on the first reading. Not because the data have changed. Because you have.

On a first reading, most figures are taken in a vacuum: there are no laboratory results to compare them with, no clinical experience to suggest which measures are most relevant to you personally. A year or two later, that context appears. The genetic data begin to resonate with real observations and turn from an abstraction into a tool.

This is why a genetic report is better regarded not as a one-off procedure but as a base layer of health information, worth turning to at every significant change in your life or your condition. It does not go out of date; it matures alongside your understanding of your own body.

The Report Stays Accurate — Your Context Grows Deeper

Your DNA does not change. The science that describes it changes, and so do you. These two processes make returning to the report not merely possible but useful: new studies refine the risk models, and new personal experience lets you read the same figures with a different level of understanding.

A genetic report is not a photograph of your health on a particular date. It is a map of your biological individuality, and it stays relevant no matter when you open it.

If you have not yet taken a test, or you want to broaden your genetic picture, take a look at the Apixmed Prism genetic testing directions.

The results of a genetic test are not a diagnosis and not a substitute for a doctor’s consultation. An Apixmed Prism report provides genetic context that complements the findings of medical examinations and helps you make decisions together with your doctor.

References

1. Manolio, T. A. (2010). Genomewide association studies and assessment of the risk of disease. New England Journal of Medicine, 363(2), 166–176. https://doi.org/10.1056/NEJMra0905980

2. Wand, H., Lambert, S. A., Tamburro, C., et al. (2021). Improving reporting standards for polygenic scores in risk prediction studies. Nature Medicine, 27, 1742–1748. https://doi.org/10.1038/s41591-021-01549-6

3. Slunecka, J. L., van der Zee, M. D., Beck, J. J., et al. (2021). Implementation and implications for polygenic risk scores in healthcare. Human Genomics, 15(1), 46. https://doi.org/10.1186/s40246-021-00339-y

4. Koch, S., Schmidtke, J., Krawczak, M., Caliebe, A. (2023). Clinical utility of polygenic risk scores: a critical 2023 appraisal. Journal of Community Genetics, 14(5), 471–481. https://doi.org/10.1007/s12687-023-00645-z